Carcopino C, Erdogan E, Henrich M, Kobold S
Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the University Hospital of the LMU, Heidelberg, Germany.
Immunooncol Technol. 2024 Sep 25;24:100739. doi: 10.1016/j.iotech.2024.100739. eCollection 2024 Dec.
Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a powerful weapon in the fight against cancer. However, its efficacy is often hindered by challenges such as limited tumor penetration, antigen escape, and immune suppression within the tumor microenvironment. This review explores the potential of armored CAR-T cells, or 'micropharmacies', in overcoming these obstacles and enhancing the therapeutic outcomes of adoptive T-cell (ATC) therapy. We delve into the engineering strategies behind these advanced therapies and the mechanisms through which they improve CAR-T-cell efficacy. Additionally, we discuss the latest advancements and research findings in the field, providing a comprehensive understanding of the role of armored CAR-T cells in cancer treatment. Ultimately, this review highlights the promising future of integrating micropharmacies into ATC therapy, paving the way for more effective and targeted cancer treatments.
嵌合抗原受体（CAR）-T细胞疗法已成为对抗癌症的有力武器。然而，其疗效常常受到诸如肿瘤浸润受限、抗原逃逸以及肿瘤微环境内免疫抑制等挑战的阻碍。本综述探讨了武装CAR-T细胞（即“微型药房”）在克服这些障碍以及提高过继性T细胞（ATC）疗法治疗效果方面的潜力。我们深入研究了这些先进疗法背后的工程策略以及它们提高CAR-T细胞疗效的机制。此外，我们讨论了该领域的最新进展和研究成果，全面了解武装CAR-T细胞在癌症治疗中的作用。最终，本综述突出了将微型药房整合到ATC疗法中充满希望的未来，为更有效、更有针对性的癌症治疗铺平道路。
